Evidence map›Paper›PMID 39043405›Full record

ArticleEmerging infectious diseases2024

Fatal SARS-CoV-2 Infection among Children, Japan, January-September 2022

Shingo Mitsushima, Yuichiro Yahata, Yuuki Tsuchihashi, Chiaki Ikenoue, Munehisa Fukusumi, Shogo Otake, Tomoe Shimada, Takuya Yamagishi, Hajime Kamiya, Yusuke Kobayashi and 26 more

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Shingo Mitsushima
Yuichiro Yahata
Yuuki Tsuchihashi
Chiaki Ikenoue
Munehisa Fukusumi
Shogo Otake
Tomoe Shimada
Takuya Yamagishi
Hajime Kamiya
Yusuke Kobayashi
Hitomi Kurosu
Mai Okuyama
Saeko Morino
Miho Shibamura
Sayaka Takanashi
Taro Kamigaki
Kanako Otani
Manami Nakashita
Hanae Ito
Ayako Miyazaki
Masaya Koshiko
Masanao Harakuni
Megumi Onuma
Hiroko Chiba
Maki Masutani
Natsu Sudani
Yuka Satsuki
Taketoshi Takara
Akira Oka
Tomohiro Katsuta
Naoki Shimizu
Akihiko Saitoh
Tetsuya Sakamoto
Motoi Suzuki
Tomimasa Sunagawa
COVID-19 Fatal Pediatric Cases Database Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the characteristics of pediatric patients 0-19 years of age who died after onset of SARS-CoV-2 infection in Japan during January 1-September 30, 2022, we reviewed multiple sources. We identified 62 cases, collected detailed information from medical records and death certificates, and conducted interviews, resulting in 53 patients with detailed information for our study. Among 46 patients with internal causes of death (i.e., not external causes such as trauma), 15% were <1 year of age, 59% had no underlying disease, and 88% eligible for vaccination were unvaccinated. Nonrespiratory symptoms were more common than respiratory symptoms. Out-of-hospital cardiac arrest affected 46% of patients, and time from symptom onset to death was <7 days for 77%. Main suspected causes of death were central nervous system abnormalities (35%) and cardiac abnormalities (20%). We recommend careful follow-up of pediatric patients after SARS-CoV-2 infection during the first week after symptom onset, regardless of underlying diseases.

Indexed as

COVID-19SARS-CoV-2AdolescentChildChild, PreschoolFemaleHumansInfantInfant, NewbornJapanMaleYoung Adult2019 novel coronavirus diseasechildrencoronavirus diseaseCOVID-19deathencephalopathyJapanmyocarditispediatricsrespiratory infectionsSARS-CoV-2severe acute respiratory syndrome coronavirus 2underlying diseaseviruseszoonoses

Identifiers

PMID39043405
PMCPMC11286078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.